High response rates for stage 1-II indolent B-cell lymphoma with yttrium-90 ibritumomab tiuxetan (Zevalin)

被引：0
|
作者：
Samaniego, F. [1 ]
Pro, B. [1 ]
Nunez, R. [1 ]
McLaughlin, P. [1 ]
Fanale, M. [1 ]
Kwak, L. [1 ]
Romaguera, J. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：208 / 208
页数：1
相关论文
共 50 条
  • [31] Clinical outcomes of post-remission therapy using 90yttrium ibritumomab tiuxetan (Zevalin®) for high-risk patients with diffuse large B-cell lymphoma
    Eun Ji Han
    Sung-Eun Lee
    Sung Hoon Kim
    Hyung Sun Sohn
    Seung Eun Jung
    Gyeongsin Park
    Byung-Ock Choi
    Sang-Nam Lee
    Suk-Woo Yang
    Kyungja Han
    Seok-Goo Cho
    Annals of Hematology, 2011, 90 : 1075 - 1082
  • [32] A phase ii study of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) for treatment of patients with relapsed and refractory mantle cell lymphoma (MCL)
    Younes, A
    Rodriguez, M
    Pro, B
    McLaughlin, P
    Romaguera, J
    Hagemeister, F
    Wang, M
    ANNALS OF ONCOLOGY, 2005, 16 : 96 - 96
  • [33] A phase II study of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) for treatment of patients with relapsed and refractory mantle cell lymphoma (MCL).
    Oki, Y
    Pro, B
    Delpassand, E
    Ballaster, V
    McLaughlin, P
    Romaguera, J
    Wang, M
    Hagemeister, FB
    Younes, A
    BLOOD, 2004, 104 (11) : 720A - 720A
  • [34] Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in primary cutaneous B-cell lymphomas: first results of a prospective, monocentre study
    Maza, Sofiane
    Gellrich, Sylke
    Assaf, Chalid
    Beyer, Marc
    Spilker, Laura
    Orawa, Helmut
    Munz, Dieter L.
    Sterry, Wolfram
    Steinhoff, Matthias
    LEUKEMIA & LYMPHOMA, 2008, 49 (09) : 1702 - 1709
  • [35] EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin)
    Tennvall, Jan
    Fischer, Manfred
    Delaloye, Angelika Bischof
    Bombardieri, Emilio
    Bodei, Lisa
    Giammarile, Francesco
    Lassmann, Michael
    Oyen, Wim
    Brans, Boudewijn
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 (04) : 616 - 622
  • [36] EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin)
    Jan Tennvall
    Manfred Fischer
    Angelika Bischof Delaloye
    Emilio Bombardieri
    Lisa Bodei
    Francesco Giammarile
    Michael Lassmann
    Wim Oyen
    Boudewijn Brans
    European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34 : 616 - 622
  • [37] Efficacy of Yttrium-90 Iburitumomab Tiuxetan for Early Relapsed/Refractory Indolent B-Cell Lymphoma: A Single Institute Retrospective Analysis in the Rituximab Era
    Nakata, Keiichi
    Fuji, Shigeo
    Nakata, Ryo
    Tsutsumi, Kazuhito
    Kida, Shuhei
    Koike, Midori
    Tada, Yuma
    Masaie, Hiroaki
    Yoshida, Hitoshi
    Ishikawa, Jun
    BLOOD, 2018, 132
  • [38] Upfront Consolidation Combining Yttrium-90 Ibritumomab Tiuxetan and High Dose Therapy with Stem-Cell Transplantation in Poor Risk Patients with Diffuse Large B-Cell Lymphoma
    Fruchart, Christophe
    Briere, Josette
    Ciappuccini, Renaud
    Casasnovas, Olivier
    Tilly, Herve
    Morschhauser, Franck
    Sebban, Catherine
    Salles, Gilles
    Ferme, Christophe
    Van Hoof, Achiel
    Bordessoule, Dominique
    Bouabdallah, Reda
    Delmer, Alain
    Gisselbrecht, Christian
    BLOOD, 2012, 120 (21)
  • [39] Activity of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) in 22 patients with relapsed and refractory mantle cell lymphoma (MCL).
    Younes, A
    Pro, B
    Rodriguez, MA
    Romaguera, JE
    McLaughlin, P
    Wang, M
    Hagemeister, FB
    Dang, NH
    Neelapu, S
    Podoloff, D
    BLOOD, 2005, 106 (11) : 689A - 690A
  • [40] Role of yttrium-90 Ibritumomab tiuxetan (Zevalin®) in inducing and maintaining complete molecular response in B non Hodgkin's lymphoma patients in clinical complete remission after chemotherapy regimen
    Orciuolo, Enrico
    Buda, Gabriele
    Galimberti, Sara
    Boni, Giuseppe
    Cecconi, Nadia
    Petrini, Mario
    BLOOD, 2007, 110 (11) : 196B - 196B
12345